Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

21. Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial Full Text available with Trip Pro

Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial Schizophrenia is a leading cause of disability, and a shift from facility- to community-based care has been proposed to meet the resource challenges of mental healthcare in low- and middle-income countries. We hypothesized that the addition of mobile texting would improve (...) schizophrenia care in a resource-poor community setting compared with a community-based free-medicine program alone.In this 2-arm randomized controlled trial, 278 community-dwelling villagers (patient participants) were randomly selected from people with schizophrenia from 9 townships of Hunan, China, and were randomized 1:1 into 2 groups. The program participants were recruited between May 1, 2015, and August 31, 2015, and the intervention and follow-up took place between December 15, 2015, and July 1

2019 EvidenceUpdates

22. Haloperidol discontinuation for people with schizophrenia. Full Text available with Trip Pro

Haloperidol discontinuation for people with schizophrenia. Schizophrenia is a disabling serious mental illness that can be chronic. Haloperidol, one of the first generation of antipsychotic drugs, is effective in the treatment of schizophrenia but can have adverse side effects. The effects of stopping haloperidol in people with schizophrenia who are stable on their prescription are not well researched in the context of systematic reviews.To review the effects of haloperidol discontinuation (...) in people with schizophrenia who are stable on haloperidol.On 20 February 2015, 24 May 2017, and 12 January 2019, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials including trial registers.We included clinical trials randomising adults with schizophrenia or related disorders who were receiving haloperidol, and were stable. We included trials that randomised such participants to either continue their current treatment with haloperidol or discontinue their haloperidol

2019 Cochrane

23. Yoga as part of a package of care versus non-standard care for schizophrenia. Full Text available with Trip Pro

Yoga as part of a package of care versus non-standard care for schizophrenia. Yoga is an ancient body-mind practice which originated in India and is popular in the Western world as a form of relaxation and exercise. It has been of interest for people with schizophrenia to determine the efficacy of yoga delivered as a package of care versus non-standard care.To examine the effects of yoga as part of a package of care versus non-standard care for schizophrenia.We searched the Cochrane (...) Schizophrenia Group Trials Register (latest 15 May 2018) which is based on regular searches of MEDLINE, PubMed, Embase, CINAHL, BIOSS, AMED, PsychINFO, and registries of clinical trials. We searched the references of all included studies. There are no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) including people with schizophrenia comparing yoga as part of a package of care with non-standard care.There were

2019 Cochrane

24. Music Therapy as Treatment of Negative Symptoms for Adult Patients Diagnosed with Schizophrenia-Study Protocol for a Randomized, Controlled and Blinded Study. Full Text available with Trip Pro

Music Therapy as Treatment of Negative Symptoms for Adult Patients Diagnosed with Schizophrenia-Study Protocol for a Randomized, Controlled and Blinded Study. Background: Three Cochrane reviews show that music therapy has a positive effect on schizophrenia concerning general functioning and positive/negative symptoms. This study aims to replicate these results in the Danish health system, a requirement for recommendation in guidelines from the Danish National Board of Health. Methods: The study (...) is a randomized, controlled multi-site study, with a blinded design, aiming to include 90 participants who are 18⁻65 years in age, diagnosed according to ICD-10 with a schizophrenia diagnosis. The participants are randomized to one of two different music therapy activities for 25 weekly sessions. The study interventions are added to standard care. Outcome measures are rated at baseline, after 15 sessions and post therapy. A qualitative interview is performed as a one month follow up at the end of study

2019 Medicines (Basel, Switzerland) Controlled trial quality: uncertain

25. Adherence therapy for schizophrenia: a randomised controlled trial. (Abstract)

Adherence therapy for schizophrenia: a randomised controlled trial. 30674700 2019 01 24 1024-2708 25 Suppl 2 2019 Feb Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Adherence therapy for schizophrenia: a randomised controlled trial. 4-9 Chien W T WT Nethersole School of Nursing, The Chinese University of Hong Kong. Cheung E Fc EF Castle Peak Hospital, Hospital Authority, Hong Kong. Mui J Hc JH Castle Peak Hospital, Hospital Authority, Hong Kong. Gray R R Faculty of Medicine

2019 Hong Kong medical journal = Xianggang yi xue za zhi Controlled trial quality: predicted high

26. Schizophrenia TreAtment with electRic Transcranial Stimulation (STARTS): design, rationale and objectives of a randomized, double-blinded, sham-controlled trial. Full Text available with Trip Pro

Schizophrenia TreAtment with electRic Transcranial Stimulation (STARTS): design, rationale and objectives of a randomized, double-blinded, sham-controlled trial. Schizophrenia is a severe mental disorder. While some antipsychotic medications have demonstrated efficacy in treating positive symptoms, there is no widely recognized treatment for negative symptoms, which can cause significant distress and impairment for patients with schizophrenia. Here we describe the rationale and design (...) of the STARTS study (Schizophrenia TreAtment with electRic Transcranial Stimulation), a clinical trial aimed to test the efficacy of a non-pharmacological treatment known as transcranial direct current stimulation (tDCS) for treating the negative symptoms of schizophrenia.The STARTS study is designed as a randomized, sham-controlled, double-blinded trial evaluating tDCS for the treatment of the negative symptoms of schizophrenia. One-hundred patients will be enrolled and submitted to 10 tDCS sessions over

2019 Trends in psychiatry and psychotherapy Controlled trial quality: predicted high

27. Psychosis and schizophrenia: What monitoring is required?

Psychosis and schizophrenia: What monitoring is required? Monitoring | Prescribing information | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Monitoring Psychosis and schizophrenia: What monitoring is required? Last revised in January 2020 What monitoring is required? When antipsychotics are initiated, baseline measurements should be taken in secondary care. People with a psychotic disorder will remain under the responsibility of the secondary care team for the first 12 months

2019 NICE Clinical Knowledge Summaries

28. Psychosis and schizophrenia: What else might it be?

Psychosis and schizophrenia: What else might it be? Differential diagnosis | Diagnosis | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Differential diagnosis Psychosis and schizophrenia: What else might it be? Last revised in January 2020 What else might it be? The differential diagnoses of psychotic disorders include: Severe affective (mood) disorders associated with psychotic symptoms, including severe depression or bipolar disorder. These conditions are distinguished from (...) schizophrenia by the predominance of affective symptoms that may at times trigger psychosis. In contrast, schizophrenia is dominated by psychotic symptoms that may at times be associated with affective symptoms. For more information, see the prodigy topics on and . Drug-induced psychosis caused by cannabis, corticosteroids, opioids, cocaine, or amphetamines. Sepsis — consider in people without a prior history of psychotic symptoms, particularly where there are features suggestive of specific infection

2019 NICE Clinical Knowledge Summaries

29. Psychosis and schizophrenia: Scenario: Women of childbearing age with psychosis or schizophrenia

Psychosis and schizophrenia: Scenario: Women of childbearing age with psychosis or schizophrenia Scenario: Women of childbearing age | Management | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Scenario: Women of childbearing age Psychosis and schizophrenia: Scenario: Women of childbearing age with psychosis or schizophrenia Last revised in January 2020 Scenario: Women of childbearing age with psychosis or schizophrenia From age 18 years onwards. How should I manage a woman (...) with psychosis or schizophrenia who is planning a pregnancy or presents with unplanned pregnancy? Refer women who are pregnant or planning a pregnancy to a specialist perinatal mental health service if available, or to the community mental health service for an assessment and discussion of drug treatment. Do not alter or stop drug treatment (and advise the woman not to alter her own medication) without seeking specialist advice. Explain to the woman that following discussion with a specialist of the risks

2019 NICE Clinical Knowledge Summaries

30. Psychosis and schizophrenia: Scenario: The routine schizophrenia or psychosis review

Psychosis and schizophrenia: Scenario: The routine schizophrenia or psychosis review Scenario: The routine schizophrenia or psychosis review | Management | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Scenario: The routine schizophrenia or psychosis review Psychosis and schizophrenia: Scenario: The routine schizophrenia or psychosis review Last revised in January 2020 Scenario: The routine schizophrenia or psychosis review From age 18 years onwards. How should I conduct a routine (...) health review of someone with psychosis or schizophrenia? Arrange review in primary care at least annually to assess the mental and physical health needs of the person. The secondary care team should maintain responsibility for monitoring the person's physical health and the effects of any antipsychotic medication for the first 12 months of treatment, or until the person's condition has stabilised (whichever is the longest). After this, the responsibility for monitoring may be transferred to primary

2019 NICE Clinical Knowledge Summaries

31. Psychosis and schizophrenia: Scenario: Managing relapse of an established psychotic disorder

Psychosis and schizophrenia: Scenario: Managing relapse of an established psychotic disorder Scenario: Managing relapse | Management | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Scenario: Managing relapse Psychosis and schizophrenia: Scenario: Managing relapse of an established psychotic disorder Last revised in January 2020 Scenario: Managing relapse of an established psychotic disorder From age 18 years onwards. How should I manage people with an established psychotic disorder (...) and Care Excellence (NICE) guideline Psychosis and schizophrenia in adults: prevention and management [ ]. Assessment of the risk of suicide and self-harm The recommendations on assessing the risk of suicide and self-harm derive from expert opinion in narrative review articles on How to approach psychotic symptoms in a non-specialist setting [ ], Early psychosis for the non-specialist doctor [ ], and Schizophrenia [ ] [ ]. Assessment of risk of harm to others The recommendations on assessing the risk

2019 NICE Clinical Knowledge Summaries

32. Psychosis and schizophrenia: Scenario: Primary care management

Psychosis and schizophrenia: Scenario: Primary care management Scenario: Primary care management | Management | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Scenario: Primary care management Psychosis and schizophrenia: Scenario: Primary care management Last revised in January 2020 Scenario: Primary care management From age 18 years onwards. How should I manage someone at risk of psychosis, with a first episode of psychosis, or with a confirmed diagnosis? For all people (...) information, see the section on . Basis for recommendation Recommendations on how to manage people experiencing frank psychosis and those at risk of developing a psychotic disorder are largely based on expert opinion within the National Institute for Health and Care Excellence (NICE) guideline Psychosis and schizophrenia in adults: prevention and management [ ]. Assessment of the risk of suicide and self-harm The recommendations on assessing the risk of suicide and self-harm derive from expert opinion

2019 NICE Clinical Knowledge Summaries

33. Psychosis and schizophrenia: How do I identify a person at risk of developing a psychotic disorder or experiencing psychosis?

Psychosis and schizophrenia: How do I identify a person at risk of developing a psychotic disorder or experiencing psychosis? Identifying someone at risk of a psychotic disorder or experiencing their first episode of psychosis | Diagnosis | Psychosis and schizophrenia | CKS | NICE Search CKS… Menu Identifying someone at risk of a psychotic disorder or experiencing their first episode of psychosis Psychosis and schizophrenia: How do I identify a person at risk of developing a psychotic disorder (...) (particularly a first-degree relative with psychosis or schizophrenia) should also raise clinical suspicion in a person exhibiting deterioration in personal and social functioning. Be aware of other for psychosis and in particular, consider asking the person about any recent or past stressful or traumatic experiences and whether they have used cannabis. Positive symptoms may not be readily disclosed by the person. It may, therefore, be necessary to directly ask them whether they are experiencing

2019 NICE Clinical Knowledge Summaries

34. Pharmacological interventions: Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t)

Pharmacological interventions: Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t) Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t) | Evidence-Based Mental Health Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t) Article Text Commentary Pharmacological interventions Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t) Marco Solmi 1 , 2 , Christoph U Correll 3 , 4 , 5 , 6 Statistics from Altmetric.com Commentary

2019 Evidence-Based Mental Health

35. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial Full Text available with Trip Pro

Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial Obesity is a major challenge for people with schizophrenia.AimsWe assessed whether STEPWISE, a theory-based, group structured lifestyle education programme could support weight reduction in people with schizophrenia.In this randomised controlled trial (study registration: ISRCTN19447796), we recruited adults with schizophrenia

2018 EvidenceUpdates

36. Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder Full Text available with Trip Pro

Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder Patients with schizophrenia or bipolar disorder have a high risk of developing type 2 diabetes.To identify predictive factors for hyperglycaemic progression in individuals with schizophrenia or bipolar disorder and to determine whether hyperglycaemic progression rates differ among antipsychotics in regular clinical practice.We recruited 1166 patients who initially had normal or prediabetic

2018 BJPsych open

37. Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department Full Text available with Trip Pro

Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department Cognitive impairment is a core feature and shows the highest impact on functional outcome in patients with schizophrenia. There have been no previous studies investigating the role of the pharmacist in a multidisciplinary team on cognitive outcomes in patients with schizophrenia.We evaluated the impact of pharmacist intervention on cognitive (...) outcomes in patients with schizophrenia by focusing on anticholinergic discontinuation.A prospective, open-label, randomized, controlled study was conducted. Patients with schizophrenia were randomly assigned to either the pharmacist intervention or usual care groups. In the pharmacist intervention group, the pharmacist identified drug-related problems (DRPs) and provided a pharmacotherapy suggestion, while there was no intervention in the usual care group. The primary outcome was mean change from

2018 Integrated pharmacy research & practice Controlled trial quality: uncertain

38. Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. Full Text available with Trip Pro

Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. Schizophrenia is a severe mental health condition that is characterised by positive symptoms, such as hallucinations and delusions; negative symptoms, such as flattened affect, thought disorder (disrupted speech), and lack of motivation; and cognitive symptoms, such as problems with memory and attention. Schizophrenia can occur as an isolated episode, or as a recurring cycle of remission (...) and relapse, and is associated with impairment in psychosocial and occupational functioning.Although antipsychotic drugs are the main treatment for people with schizophrenia, in most countries mental health services usually provide a range of add-on interventions, including occupational therapy. This is a complex intervention designed to support and enable continued participation in daily life through engagement in activities and occupations meaningful to the individual. Occupational therapists

2018 Cochrane

39. Culturally adapted Family Intervention (CaFI) for African-Caribbean people diagnosed with schizophrenia and their families: a mixed-methods feasibility study of development, implementation and acceptability Full Text available with Trip Pro

Culturally adapted Family Intervention (CaFI) for African-Caribbean people diagnosed with schizophrenia and their families: a mixed-methods feasibility study of development, implementation and acceptability Culturally adapted Family Intervention (CaFI) for African-Caribbean people diagnosed with schizophrenia and their families: a mixed-methods feasibility study of development, implementation and acceptability Journals Library An error occurred retrieving content to display, please try again (...) . >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} It proved feasible to culturally adapt and test family intervention with African-Caribbean people with schizophrenia and their families, and the study yielded high rates of recruitment, attendance, retention

2018 NIHR HTA programme

40. Schizophrenia

Schizophrenia Top results for schizophrenia - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for schizophrenia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest